[{"id":"be0a0acb-715b-4bf3-8af3-8a6314e2a31f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06514261","created_at":"2025-02-25T20:15:15.595Z","updated_at":"2025-02-25T20:15:15.595Z","phase":"Phase 1","brief_title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","source_id_and_acronym":"NCT06514261","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX","pipe":"","alterations":" ","tags":["TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • iadademstat (ORY-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/18/2024","start_date":" 12/18/2024","primary_txt":" Primary completion: 09/16/2026","primary_completion_date":" 09/16/2026","study_txt":" Completion: 09/16/2026","study_completion_date":" 09/16/2026","last_update_posted":"2025-01-16"},{"id":"370a32d3-7f84-4b34-a0c4-86832be5fec0","acronym":"FRIDA","url":"https://clinicaltrials.gov/study/NCT05546580","created_at":"2022-09-21T21:56:59.855Z","updated_at":"2024-07-02T16:35:18.799Z","phase":"Phase 1","brief_title":"Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)","source_id_and_acronym":"NCT05546580 - FRIDA","lead_sponsor":"Oryzon Genomics S.A.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • iadademstat (ORY-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2024-02-19"}]